22Z.F Zealand Pharma A/S

Healthcare Biotechnology Frankfurt Exchange
32.95 EUR
Close of Nov 12, 2026
29.38 73.80
Market cap
EUR 2.19B
P/E
6.4x
P/B
0.90x
ROE
39.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 22Z.F undervalued?

Graham number
Price32.95
Graham value65.01
Discount49.3%

22Z.F trades 49.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Zealand Pharma A/S fundamental analysis

No fundamental analysis for Zealand Pharma A/S yet.

Zealand Pharma A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas sys…

Full company profile